Xconomy Forum: Building Biotechs to Last

Biotech is a long-term business, but it depends on an investment world more focused on the short term. Many companies have slashed R&D budgets, cut corners in clinical development, or done shotgun marriage megamergers to satisfy Wall Street’s desire for improved results by next Tuesday. But there are still a few companies in biotech who are willing and able to buck the trend. They have a strategy for the long haul, and the guts to stick with it. Join Xconomy’s national biotech editor, Luke Timmerman, for a series of 1-on-1 interviews with executives and directors who will talk about cases in which they put their company’s long-term strategy ahead of short-term considerations, even when it posed a serious risk to the company, or wasn’t the popular thing to do.

Confirmed Speakers:

  • Stanley Crooke
    • Founder, Chairman, and CEO, Isis Pharmaceuticals
  • Kim Popovits
    • Chairman and CEO, Genomic Health
  • Bryan Roberts
    • Partner, Venrock Associates
  • Chris Garabedian
    • CEO, Sarepta Therapeutics
  • Bob More
    • Senior Advisor, Bill & Melinda Gates Foundation
  • Adelene Perkins
    • CEO, Infinity Pharmaceuticals
  • Paul Hastings
    • CEO, OncoMed Pharmaceuticals
  • Bonnie Anderson
    • President and CEO, Veracyte

Follow us on Twitter:




Registration & Networking: 1:00 – 2:00 pm

Program: 2:00 – 5:30 pm

Networking reception: 5:30 – 6:30 pm

Registration Information

Saver Rate (ends Nov. 19): $250

Regular Registration: $295

Startup Special: $175

Student Registration: $35

At the Door: $375

Register Now

Kilpatrick Townsend
Kilpatrick Townsend            Silicon Valley Bank
Health Advances       Sarepta
BayBio   Women in Bio